Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

CXL Ophthalmics

Request full access

A clinical-stage company developing a minimally-invasive treatment for keratoconus

Burlington, United StatesHealth Tech & Medtech

About CXL Ophthalmics

CXL Ophthalmics, which rebranded as Epion Therapeutics in July 2023, is a clinical-stage biopharmaceutical company focused on developing treatments for ectatic corneal diseases. The company was founded in 2012 and is headquartered in Burlington, Massachusetts. Michael D. Webb serves as the President and Chief Executive Officer, bringing over 25 years of entrepreneurial experience in healthcare and life sciences, specializing in early-stage companies. The company's Chief Medical Officer is Dr. Michael Belin, and its Chief Scientific Officer is Dr. Roy Rubinfeld.

The company is centered on the development of its proprietary EpiSmart system, a drug-device combination for performing minimally-invasive, epithelium-on (epi-on) corneal cross-linking (CXL). This procedure is designed to treat keratoconus, a progressive eye disease where the cornea thins and bulges into a cone-like shape, causing distorted vision. Unlike the traditional FDA-approved "epi-off" method that requires the surgical removal of the cornea's outer layer (the epithelium), EpiSmart's approach preserves this layer. This key difference aims to reduce patient discomfort, lower the risk of infection, and significantly shorten recovery time, with patients potentially returning to normal activities within a couple of days. The business model revolves around gaining FDA approval for the EpiSmart system and commercializing it for use by ophthalmologists and eye care professionals. The target market includes millions of patients globally who suffer from keratoconus and could benefit from an earlier, less invasive intervention.

The EpiSmart system consists of a riboflavin drug formulation (RiboStat) and a UVA light delivery device. The procedure involves applying the proprietary riboflavin solution, which is designed to penetrate the intact epithelium, followed by a controlled application of UVA light to strengthen the collagen fibers within the cornea. A significant feature is the potential for simultaneous bilateral treatment, allowing both eyes to be treated at the same time. In September 2022, the company secured a $32 million Series A funding round led by AXA IM Alts to advance the EpiSmart system through Phase 3 clinical trials toward a New Drug Application with the FDA. Results from its extensive Phase 2 trial, the largest of its kind with over 2,200 subjects, showed promising safety and efficacy, with 80% of patients maintaining or improving their corrected vision 12 months post-operation and experiencing fewer adverse events compared to the epi-off standard of care.

Source: Dealroom company data

At a glance

Status
Operational
Employees
7
Open positions
None listed
Dealroom signal
26.7/100
Industry
Health
Sub-industry
Medical Devices
Sector
Hard Tech
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Sep 2022 $32M $128M AXA Investment Managers ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

CXL Ophthalmics website traffic

Latest recorded traffic for CXL Ophthalmics is 240 monthly website visits, up 140% over the last three months. CXL Ophthalmics's team grew 0% over the past year.

Latest monthly visits240 3-month web change+140% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

CXL Ophthalmics in the Burlington ecosystem

Live from Dealroom

The CXL Ophthalmics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • AXA Investment Managers
Employees 7 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about CXL Ophthalmics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See CXL Ophthalmics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.